FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma

References

1. 1.↵
   2. Bray F,
   3. Ferlay J,
   4. Soerjomataram I,
   5. Siegel RL,
   6. Torre LA,
   7. Jemal A.

   Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Siegel RL,
   3. Miller KD,
   4. Jemal A.

   Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7–34.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Chen W,
   3. Sun K,
   4. Zheng R,
   5. Zeng H,
   6. Zhang S,
   7. Xia C, et al.

   Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018; 30: 1–12.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Babina IS,
   3. Turner NC.

   Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17: 318–32.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Thoma C.

   Prostate cancer: targeting the FGFR curbs bone metastasis. Nat Rev Urol. 2014; 11: 604.
6. 6.↵
   2. De Keukeleire S,
   3. De Maeseneer D,
   4. Jacobs C,
   5. Rottey S.

   Targeting FGFR in bladder cancer: ready for clinical practice? Acta Clin Belg. 2020; 75: 49–56.

   OpenUrl
7. 7.↵
   2. Chen CH,
   3. Changou CA,
   4. Hsieh TH,
   5. Lee YC,
   6. Chu CY,
   7. Hsu KC, et al.

   Dual inhibition of PIK3C3 and FGFR as a new therapeutic approach to treat bladder cancer. Clin Cancer Res. 2018; 24: 1176–89.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Qin A,
   3. Johnson A,
   4. Ross JS,
   5. Miller VA,
   6. Ali SM,
   7. Schrock AB, et al.

   Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J Thorac Oncol. 2019; 14: 54–62.

   OpenUrl
9. 9.↵
   2. Flockerzi FA,
   3. Roggia C,
   4. Langer F,
   5. Holleczek B,
   6. Bohle RM.

   FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer. Virchows Arch. 2018; 472: 759–69.

   OpenUrl
10. 10.↵
    2. Fumarola C,
    3. Cretella D,
    4. La Monica S,
    5. Bonelli MA,
    6. Alfieri R,
    7. Caffarra C, et al.

    Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. Oncotarget. 2017; 8: 91841–59.

    OpenUrl
11. 11.↵
    2. Chang J,
    3. Liu X,
    4. Wang S,
    5. Zhang Z,
    6. Wu Z,
    7. Zhang X, et al.

    Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis. PLoS One. 2014; 9: e105524.
12. 12.↵
    2. Calandrella N,
    3. Risuleo G,
    4. Scarsella G,
    5. Mustazza C,
    6. Castelli M,
    7. Galati F, et al.

    Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor. J Exp Clin Cancer Res. 2007; 26: 405–9.

    OpenUrlPubMed
13. 13.↵
    2. Li JJ,
    3. Xie D.

    RACK1, a versatile hub in cancer. Oncogene. 2015; 34: 1890–8.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Choi YY,
    3. Lee SY,
    4. Lee WK,
    5. Jeon HS,
    6. Lee EB,
    7. Lee HC, et al.

    RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer. Oncotarget. 2015; 6: 4451–66.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Shi S,
    3. Deng YZ,
    4. Zhao JS,
    5. Ji XD,
    6. Shi J,
    7. Feng YX, et al.

    RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. J Biol Chem. 2012; 287: 7845–58.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    2. Zhou C,
    3. Chen T,
    4. Xie Z,
    5. Qin Y,
    6. Ou Y,
    7. Zhang J, et al.

    RACK1 forms a complex with FGFR1 and PKM2, and stimulates the growth and migration of squamous lung cancer cells. Mol Carcinog. 2017; 56: 2391–99.

    OpenUrl
17. 17.↵
    2. Faget DV,
    3. Ren Q,
    4. Stewart SA.

    Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019; 19: 439–53.

    OpenUrlPubMed
18. 18.↵
    2. Mathon NF,
    3. Lloyd AC.

    Cell senescence and cancer. Nat Rev Cancer. 2001; 1: 203–13.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Campisi J.

    Cancer and ageing: rival demons? Nat Rev Cancer. 2003; 3: 339–49.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    2. Schmitt CA.

    Senescence, apoptosis and therapy–cutting the lifelines of cancer. Nat Rev Cancer. 2003; 3: 286–95.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    2. Adachi Y,
    3. Watanabe K,
    4. Kita K,
    5. Kitai H,
    6. Kotani H,
    7. Sato Y, et al.

    Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Carcinogenesis. 2017; 38: 1063–72.

    OpenUrl
22. 22.↵
    2. Javle M,
    3. Lowery M,
    4. Shroff RT,
    5. Weiss KH,
    6. Springfeld C,
    7. Borad MJ, et al.

    Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018; 36: 276–82.

    OpenUrlCrossRefPubMed
23. 23.↵
    2. Dai S,
    3. Zhou Z,
    4. Chen Z,
    5. Xu G,
    6. Chen Y.

    Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells. 2019; 8: 614.